看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
, y4 k. h5 @! W& \+ o
2 L+ [. f. E3 U% H% Y* q: y) A( Y) z6 X G* C
Currently available feasibility data for possible combination strategies.
/ w" R* f) Y7 `————————————————————————————————6 S0 P" B) V* }* C S2 M0 W
Combination Feasibility according to preliminary data
, }& f) p" {2 `) L6 s; N4 t* L——————————————————————————————————- I; u7 b7 I! _+ B o
Bevacizumab + sorafenib Yes, reduced dose 6 t3 h5 l" v' \
Bevacizumab + sunitinib† No
: W6 }7 M6 U0 D3 q$ G2 aBevacizumab + temsirolimus Yes 0 R L( c9 ?0 o4 R9 i& s
Bevacizumab + everolimus Yes
( z" W, J. k7 K4 `8 _2 a7 Z7 CSorafenib + sunitinib ?
7 l" ^# k) h- ]1 D* G) x# G6 q' aSorafenib + temsirolimus Yes, reduced dose 4 @0 h5 N9 b- l6 z+ d8 D( k
Sorafenib + everolimus Yes, reduced dose
6 y( S! _ y, x* E* XSunitinib + temsirolimus† No
, Y7 v! l) f: e, L% ?. _Sunitinib + everolimus ?
9 F! t6 S7 C; p9 w% U. z# |, X! aTemsirolimus + everolimus ?
0 y, }- u; u" Q7 R# o————————————————————
" B5 }1 o& d( t G†Led to US FDA warning.# Y7 _) G t( p& @' _
?: As yet unattempted combination.
2 I( ~; x9 D' u |